A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
A phase 2 trial of Docetaxel and Gemcitabine in bladder & urothelial cancer, run by Relmada Therapeutics, Inc., now recruiting.
Overview
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC is a phase 2 interventional study registered as NCT06663137 by Relmada Therapeutics, Inc., with 70 participants planned, started 2024-08-01 and due to reach its primary completion in 2027-11. Interventions recorded: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Shares Docetaxel, Bladder & urothelial cancer and the tag pipeline.
- TrialA Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Shares Docetaxel, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Shares Docetaxel, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.